FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891368065> ?p ?o ?g. }

• W2891368065 abstract "The combination of chemotherapy and L-asparaginase (L-ASP) treatment significantly increased survival rate in an adult patient with extranodal natural killer (NK)/T-cell lymphoma (NKTCL). However, hypersensitivity reactions of L-ASP in some patients limited its application. Polyethylene glycol-conjugated asparaginase (PEG-ASP) has a lower immunogenicity and longer circulating half-life than unconjugated L-ASP, and has been reported to be effective and well-tolerated in children with acute lymphoblastic leukemia. Cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) is the most common chemotherapy for non-Hodgkin lymphoma. In this report, we sought to study the efficacy and safety of PEG-L- CHOP in NKTCL in adult Chinese patients.Our study is a prospective, multi-center, open-label clinical trial. Patients with newly diagnosed adult NKTCL and an ECOG performance status of 0 to 2 were eligible for enrollment. Treatment included six cycles of PEG-L-CHOP regimen. Radiotherapy was scheduled after 2-4 cycles of PEG-L-CHOP regimen, depending on the stage and primary anatomic site.We enrolled a total of 33 eligible patients. All 33 patients completed 170 cycles of chemotherapy combined with radical radiotherapy. The overall response rate was 96.9% (32/33) with 75.8% (25/33) achieving complete responses and 21.2% (7/33) achieving partial responses. The overall survival (OS) at 1, 2, 3-year were 100, 90.61 and 80.54%, respectively. The major adverse effects were bone marrow suppression, reduction of fibrinogen level, liver dysfunction, and digestive tract toxicities. No allergic reaction and no treatment-related mortality or severe complications were recorded.PEG-L-CHOP chemotherapy in combination radiotherapy is safe and durably effective treatment for adult extranodal NK/T-cell lymphoma with fewer allergic reactions. This study was approved by the Peking University Beijing Cancer Hospital Ethics Review Committee (reference number: 2011101104). The clinical trial registration number ChiCTR1800016940 was registered on July 07, 2018 at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/index.aspx ). The clinical trial was registered retrospectively." @default.
• W2891368065 created "2018-09-27" @default.
• W2891368065 creator A5001104633 @default.
• W2891368065 creator A5004565426 @default.
• W2891368065 creator A5004803637 @default.
• W2891368065 creator A5011385130 @default.
• W2891368065 creator A5011803798 @default.
• W2891368065 creator A5023344661 @default.
• W2891368065 creator A5027220663 @default.
• W2891368065 creator A5028076162 @default.
• W2891368065 creator A5030040961 @default.
• W2891368065 creator A5034855502 @default.
• W2891368065 creator A5061482899 @default.
• W2891368065 creator A5066795023 @default.
• W2891368065 creator A5069604153 @default.
• W2891368065 creator A5077219071 @default.
• W2891368065 creator A5077970092 @default.
• W2891368065 creator A5083037234 @default.
• W2891368065 creator A5087025928 @default.
• W2891368065 date "2018-09-21" @default.
• W2891368065 modified "2023-10-16" @default.
• W2891368065 title "PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity" @default.
• W2891368065 cites W1522552273 @default.
• W2891368065 cites W1572766205 @default.
• W2891368065 cites W1831274761 @default.
• W2891368065 cites W1942897646 @default.
• W2891368065 cites W1971341070 @default.
• W2891368065 cites W1979943942 @default.
• W2891368065 cites W1985199344 @default.
• W2891368065 cites W2002458206 @default.
• W2891368065 cites W2017968132 @default.
• W2891368065 cites W2022969561 @default.
• W2891368065 cites W2024893955 @default.
• W2891368065 cites W2040341451 @default.
• W2891368065 cites W2040724113 @default.
• W2891368065 cites W2044311824 @default.
• W2891368065 cites W2056667876 @default.
• W2891368065 cites W2060824604 @default.
• W2891368065 cites W2061947873 @default.
• W2891368065 cites W2064565700 @default.
• W2891368065 cites W2073833526 @default.
• W2891368065 cites W2087582514 @default.
• W2891368065 cites W2091292251 @default.
• W2891368065 cites W2097449310 @default.
• W2891368065 cites W2113282595 @default.
• W2891368065 cites W2117623554 @default.
• W2891368065 cites W2123822349 @default.
• W2891368065 cites W2128542104 @default.
• W2891368065 cites W2133201432 @default.
• W2891368065 cites W2134315181 @default.
• W2891368065 cites W2146096629 @default.
• W2891368065 cites W2147243327 @default.
• W2891368065 cites W2161739649 @default.
• W2891368065 cites W2163219205 @default.
• W2891368065 cites W2164520862 @default.
• W2891368065 cites W2168476975 @default.
• W2891368065 cites W2169587943 @default.
• W2891368065 cites W2313043104 @default.
• W2891368065 cites W2335410721 @default.
• W2891368065 cites W2375755647 @default.
• W2891368065 cites W2728788724 @default.
• W2891368065 cites W2767940058 @default.
• W2891368065 cites W4298074044 @default.
• W2891368065 cites W49036964 @default.
• W2891368065 cites W72578799 @default.
• W2891368065 cites W95410032 @default.
• W2891368065 doi "https://doi.org/10.1186/s12885-018-4782-y" @default.
• W2891368065 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6151061" @default.
• W2891368065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30241515" @default.
• W2891368065 hasPublicationYear "2018" @default.
• W2891368065 type Work @default.
• W2891368065 sameAs 2891368065 @default.
• W2891368065 citedByCount "8" @default.
• W2891368065 countsByYear W28913680652019 @default.
• W2891368065 countsByYear W28913680652020 @default.
• W2891368065 countsByYear W28913680652022 @default.
• W2891368065 countsByYear W28913680652023 @default.
• W2891368065 crossrefType "journal-article" @default.
• W2891368065 hasAuthorship W2891368065A5001104633 @default.
• W2891368065 hasAuthorship W2891368065A5004565426 @default.
• W2891368065 hasAuthorship W2891368065A5004803637 @default.
• W2891368065 hasAuthorship W2891368065A5011385130 @default.
• W2891368065 hasAuthorship W2891368065A5011803798 @default.
• W2891368065 hasAuthorship W2891368065A5023344661 @default.
• W2891368065 hasAuthorship W2891368065A5027220663 @default.
• W2891368065 hasAuthorship W2891368065A5028076162 @default.
• W2891368065 hasAuthorship W2891368065A5030040961 @default.
• W2891368065 hasAuthorship W2891368065A5034855502 @default.
• W2891368065 hasAuthorship W2891368065A5061482899 @default.
• W2891368065 hasAuthorship W2891368065A5066795023 @default.
• W2891368065 hasAuthorship W2891368065A5069604153 @default.
• W2891368065 hasAuthorship W2891368065A5077219071 @default.
• W2891368065 hasAuthorship W2891368065A5077970092 @default.
• W2891368065 hasAuthorship W2891368065A5083037234 @default.
• W2891368065 hasAuthorship W2891368065A5087025928 @default.
• W2891368065 hasBestOaLocation W28913680651 @default.
• W2891368065 hasConcept C126322002 @default.
• W2891368065 hasConcept C141071460 @default.
• W2891368065 hasConcept C143998085 @default.
• W2891368065 hasConcept C2776694085 @default.

• next